Visit us at booth #11 from Feb 27th-29th during Immuno-Oncology 360° in New York

What We Do

We offer a discovery service to academia, government and industry through the Serimmune universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly profile antibody repertoires and identify antigens and epitopes associated with many diseases - all in a single assay.


How We Do It

Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next-generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Through this, we gain a broad view of an individual’s environmental exposures and the unique immune responses to these exposures in disease and health.


Why We Do It

Serimmune was founded on the belief that the information coded in the individual’s functional antibody repertoire is key to understanding human disease. To fulfill this vision, we created a technology for building and interpreting a dynamic map of human immunity which continually evolves to map interactions between functional antibody repertoire and human disease. Linkages between antibody response to pathogens have been shown in oncology, autoimmune, infectious, neurodegenerative, and other complex diseases.

About Us



Target Discovery

Serimmune Biomarker Discovery Service

Learn about Serimmune’s SERA platform which combines large biological libraries, NGS, and custom bioinformatics to unlock the Circulating Antibody Repertoire to achieve hypothesis free serology.

Neutralizing Epitopes

Biomarkers of Response


Immuno-Oncology 360° Summit

February 27th-29th

New York, NY

Hear from stakeholders representing both the science and business communities who report on the latest data impacting ​​​​​​​​​​​​​​IO to fight a wider range of cancers.

Join us at Booth #11!

Contact us to schedule a meeting at

Resolve the challenges of immunogenicity testing and risk assessment during preclinical and clinical development, bioassay design & analysis, and how to manipulate the immune system for therapeutic advantage


Immunogenicity & Bioassay Summit

October 2nd-5th

Washington, D.C.

Let's Talk Science

    Areas of Interest (check all that apply):

    Academic and Government Collaborators